Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elizabeth Cairns

Senior Writer

A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.

Latest From Elizabeth Cairns

CNS Drugs Are Surprisingly Valuable

An analysis of the most valuable research-stage products pinpoints several neurological candidates – and a deeper dive into this segment shows more CNS therapies that look to be worth big money.

Clinical Trials Commercial

The Prospects For Earlier-Stage Antibody-Drug Conjugates

Around 25 ADCs are in active Phase I/II trials, with a range of mechanistic approaches.

Clinical Trials Commercial

IPOs Collapse In The Second Quarter

Biotechs have had a difficult time raising cash through flotations over the past quarter, with one stepping away altogether.

Financing Business Strategies

Inventiva Contemplates The End Of The Road

The group’s MASH candidate lanifibranor carries hefty sales forecasts but Inventiva might run out of cash before the approval trial reports.

Clinical Trials Commercial

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.

Commercial Companies

Annovis Soars On Parkinson’s Failure

Buntanetap misses the primary endpoint in another Phase III trial but investors are swayed by exploratory analyses.

Commercial Clinical Trials
See All
UsernamePublicRestriction

Register